Posted on February 8, 2012 by Sitemaster
According to an online report in The Washington Post earlier this afternoon, an advisory panel to the U.S. Food and Drug Administration (FDA) has voted 12 to 1 not to recommend the approval of denosumab (Xgeva®) for the prevention of bone metastasis in men with non-metastatic, castrate-resistant prostate cancer.
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: denosumab, metastasis, Prevention, Xgeva | Leave a Comment »
Posted on February 6, 2012 by Sitemaster
The U.S. Food and Drug Administration (FDA) has questioned the value of denosumab (Xgeva®) as an agent capable of delaying the onset of metastatic disease to bone in men with progressive, castration-resistant prostate cancer.
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: bone, denosumab, metastasis, Prevention, Xgeva | 7 Comments »
Posted on January 31, 2012 by Sitemaster
A new review of the available literature has concluded that, despite the fact that “prostate cancer is an ideal target for prevention,” there is in fact “no suitable evidence to recommend using any specific nutritional supplement or diet to prevent prostate cancer” at the present time.
Filed under: Diagnosis, Prevention, Risk | Tagged: 5-ARI, 5α-reductase inhibitor, diet, nutrition, Prevention, supplement | 1 Comment »
Posted on January 26, 2012 by Sitemaster
According to a media release we received yesterday, a new paper in the British Journal of Nutrition suggests that “walnuts may help to prevent prostate cancer risk.”
Filed under: Diagnosis, Prevention, Risk | Tagged: Prevention, risk, walnut | 1 Comment »
Posted on January 24, 2012 by Sitemaster
According to data just reported in The Lancet, some men with low-volume, low-risk prostate cancer may be able to delay progression of their disease if treated only with the 5α-reductase inhibitor dutasteride (Avodart®).
Filed under: Living with Prostate Cancer, Management, Treatment, Uncategorized | Tagged: dutasteride, low risk, Prevention, progression | 5 Comments »
Posted on November 17, 2011 by Sitemaster
The full data on the use of denosumab to delay the onset of bone metastasis in men with high-risk, progressive, non-metastatic, castration-resistant prostate cancer (CRPC) were published on line yesterday in The Lancet. We originally reported the results of this trial as presented at the annual meeting of the American Urological Association (AUA) in May [...]
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: denosumab, metastasis, Prevention, survival | Leave a Comment »
Posted on November 5, 2011 by Sitemaster
Newly reported research from a team at the Centenary Institute in Sydney, Australia, has suggested a very different way in which it may be possible to significantly delay or manage the progression of prostate cancer.
Filed under: Drugs in development, Management, Prevention | Tagged: blockade, leucine, Management, Prevention | 2 Comments »
Posted on September 19, 2011 by Sitemaster
According to a media release issued by Amgen earlier today, the U.S. Food & Drug Administration (FDA) has approved denosumab (marketed as both Prolia® and Xgeva®) as a treatment to increase bone mass in in men with non-metastatic prostate cancer who are already being treated with androgen deprivation therapy (ADT) and who are at high [...]
Filed under: Living with Prostate Cancer, Management, Prevention, Treatment | Tagged: approval, denosumab, fracture, Prevention | Leave a Comment »
Posted on September 12, 2011 by Sitemaster
Last Friday a U.S. Food & Drug Administration (FDA) advisory committee recommended (based on a 17 to 6 vote) that the labeling of bisphosphonates needed to be updated to make it clear how long patients should take these drugs to gain the greatest benefit and suffer the least risk.
Filed under: Living with Prostate Cancer, Management | Tagged: bisphosphonate, fracture, osteoporosis, Prevention, skeletal-related event | Leave a Comment »
Posted on September 1, 2011 by Sitemaster
In a newly published paper in the journal Integrative Cancer Therapies, the authors report high use of vitamins and supplements among undiagnosed men with a brother who has previously been diagnosed with prostate cancer.
Filed under: Diagnosis, Prevention, Risk | Tagged: brother, Diagnosis, family, Prevention, risk, supplement, vitamin | 1 Comment »
Posted on August 29, 2011 by Sitemaster
Clinical guidelines issued by the National Comprehensive Cancer Network recommend that prostate cancer patients being treated with androgen deprivation therapy (ADT) — either alone or in combination with radiation therapy — should be screened for osteoporosis and treatment to prevent deterioration of bone health associated with a decline in bone mineral density.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: ADT, androgen deprivation therapy, DXA, fracture, FRAX, guideline, osteopenia, osteoporesis, Prevention | 4 Comments »
Posted on August 25, 2011 by Sitemaster
The full text of a new article on the potential of whole ginger extract (WGE) in the prevention and treatment of of prostate cancer has recently been published in the British Journal of Nutrition.
Filed under: Drugs in development, Living with Prostate Cancer, Management, Prevention, Treatment, Uncategorized | Tagged: extract, ginger, Prevention, Treatment, WGE | 3 Comments »
Posted on August 22, 2011 by Sitemaster
According to a media release from Amgen earlier today, the U.S. Food & Drug Administration (FDA) has indicated that a decision will be made by April 26, 2012 about the requested expansion of the indication for denosumab (Xgeva®) to include the prevention of bone metastases in men with non-metastatic, castration-resistant prostate cancer.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: denosumab, metastasis, Prevention, survival, Xgeva | Leave a Comment »
Posted on June 16, 2011 by Sitemaster
The “New” Prostate Cancer InfoLink is delighted to see Dr. Pazdur and colleagues from the U.S. Food & Drug Administration (FDA) present their reasoning for non-approval of the 5α-reductase inhibitors (5-ARIs) dutasteride and finasteride for prevention of prostate cancer in a new article in the New England Journal of Medicine.
Filed under: Diagnosis, Living with Prostate Cancer, Prevention, Risk | Tagged: 5-ARI, 5α-reductase inhibitor, FDA, Prevention | 11 Comments »
Posted on June 10, 2011 by Sitemaster
Yesterday the US Food & Drug Administration (FDA) updated its guidance on the use of 5α-reductase inhibitors with specific reference to the risk that use of these products may be able to induce high-grade (and therefore high-risk) prostate cancer in a small subset of men treated with these agents.
Filed under: Diagnosis, Prevention, Risk | Tagged: 5-ARI, dutasteride, FDA, finasteride, Prevention, risk | 4 Comments »